ArticleScientific reports2025
Virtual screening and molecular dynamics studies of antivenom using flavonoid compounds derived from Andrographis echioides.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antivenom potential of Andrographis echioides (A. echioides), a traditional medicinal herb, was investigated using a comprehensive in silico approach to address the limitations of conventional antivenoms against Russell's viper envenomation. This study aimed to conduct virtual screening and molecular dynamics (MD) studies of flavonoid compounds from A. echioides to explore their potential as antivenom agents. Gas chromatography-mass spectrometry (GC-MS) analysis identified 84 bioactive phytochemicals in the leaf extracts. The selected flavonoid constituents were evaluated for their predicted inhibitory potential against venom-associated enzymes using molecular docking with the iGEMDOCK software. The target proteins included metalloproteinase (PDB ID: 2E3X), serine proteinase (PDB ID: 3S9A), and human pancreatic phospholipase A2 (PDB ID: 6Q42). Among the screened compounds, decanoic acid (- 93.7429 kcal/mol), oxalic acid 6-ethyloct-3-yl isohexyl ester (- 91.6448 kcal/mol), and oxalic acid 6-ethyloct-3-yl hexyl ester (- 85.7934 kcal/mol) exhibited the highest binding affinities to the target protein and compared them with the standard compound. Drug-likeness analysis confirmed the favorable pharmacokinetic properties of compounds. MD simulations spanning 100 ns revealed stable binding interactions, consistent RMSD values, favorable hydrogen bonding patterns, and stable structural dynamics. This is the first study to report the antivenom potential of bioactive compounds from this species using computational methods. These computational insights suggest that flavonoid constituents derived from A. echioides may possess promising binding and predicted inhibitory activities against key venom enzymes, warranting further investigation as potential natural antivenom agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.